Skip to main content
. 2017 Aug 11;17:651. doi: 10.1186/s12889-017-4629-5

Table 2.

Prevalence, awareness, treatment and control of hypercholesterolemia (HC) in Astana region, Kazakhstan (total cholesterol ≥6.2 mmol/l)

Men (n = 416) Women (n = 538) Both sexes (n = 954)
Prevalence 95% CI Cases/All Prevalence 95% CI Cases/All Prevalence 95% CI Cases/All
Combined Astana city and Akmol village
 Prevalence of HC among all 28.4% 24.0–32.7 118/416 44.1% 39.8–48.3 237/538 37.2% 34.1–40.3 355/954
 Awareness among all cases of HC 47.5% 38.3–56.6 56/118 61.2% 54.9–67.4 145/237 56.6% 51.4–61.8 201/355
 Treatment among all cases of HC 33.1% 24.4–41.7 39/118 44.3% 37.9–50.7 105/237 40.6% 35.4–45.7 144/355
 Treatment among aware 67.9% 55.2–80.5 38/56 71.7% 64.3–79.1 104/145 70.7% 64.3–77.0 142/201
 Control among all cases of HC 26.3% 18.2–34.3 31/118 21.9% 16.6–27.2 52/237 23.4% 19.0–27.8 83/355
 Control among treated 79.5% 66.2–92.7 31/39 49.5% 39.8–59.2 52/105 57.6% 49.5–65.8 83/144
Astana city (urban, n = 480)
 Prevalence of HC among all 38.2% 31.7–44.7 84/220 57.3% 51.3–63.4 149/260 48.5% 44.1–53.0 233/480
 Awareness among all cases of HC 56.0% 45.1–66.8 47/84 72.5% 65.2–79.7 108/149 66.5% 60.4–72.6 155/233
 Treatment among all cases of HC 36.9% 26.4–47.4 31/84 49.7% 41.5–57.8 74/149 45.1% 38.6–51.5 105/233
 Treatment among aware 63.8% 49.6–78.1 30/47 68.5% 59.6–77.4 74/108 67.1% 59.6–74.6 104/155
 Control among all cases of HC 29.8% 19.8–39.7 25/84 24.8% 17.8–31.9 37/149 26.6% 20.9–32.3 62/233
 Control among treated 80.7% 65.9–95.4 25/31 50.0% 38.3–61.7 37/74 59.1% 49.5–68.6 62/105
Akmol village (rural, n = 474)
 Prevalence of HC among all 17.4% 12.0–22.7 34/196 31.7% 26.2–37.2 88/278 25.7% 21.8–29.7 122/474
 Awareness among all cases of HC 26.5% 10.8–42.1 9/34 42.1% 31.5–52.6 37/88 37.7% 29.0–46.4 46/122
 Treatment among all cases of HC 23.5% 8.5–38.6 8/34 35.2% 25.0–45.4 31/88 32.0% 23.6–40.4 39/122
 Treatment among aware 88.9% 63.3–114.5 8/9 81.1% 67.8–94.3 30/37 82.6% 71.2–94.0 38/46
 Control among all cases of HC 17.7% 4.1–31.1 6/34 17.1% 9.0–25.1 15/88 17.2% 10.4–24.0 21/122
 Control among treated 75.0% 36.3–113.7 6/8 48.4% 29.8–67.0 15/31 53.9% 37.5–70.2 21/39